INNERCOOL Therapies Licenses New Therapeutic for Potential Use in Stroke Patients
10/22/2007 9:22:20 AM
SAN DIEGO--(BUSINESS WIRE)--Cardium Therapeutics (AMEX:CXM) and its subsidiary InnerCool Therapies today announced that it has entered into a license agreement with the University of Texas Health Science Center at Houston for the clinical research, development and commercialization of Caffeinol as a potential therapeutic for use in acute ischemic stroke patients. One of the objectives of the exclusive licensing agreement is to evaluate the safety and efficacy of treating stroke patients with Caffeinol, administered by intravenous infusion (IV), in combination with InnerCool’s endovascular hypothermia technology. A study has been proposed to the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH).
comments powered by